140 related articles for article (PubMed ID: 35723576)
1. The impact of remission duration on the long-term economic burden of acute myeloid leukemia among patients without hematopoietic stem cell transplant in the United States.
Tabah A; Brady BL; Huggar D; Jariwala-Parikh K; Huey K; Copher R; LeBlanc TW
J Med Econ; 2022; 25(1):903-911. PubMed ID: 35723576
[TBL] [Abstract][Full Text] [Related]
2. Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database.
Brunner AM; Huggar D; Copher R; Zhou ZY; Zichlin ML; Anderson A; Downes N; McBride A
Leuk Res; 2023 Sep; 132():107353. PubMed ID: 37562330
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia.
Hagiwara M; Sharma A; Chung KC; Delea TE
J Med Econ; 2018 Nov; 21(11):1119-1130. PubMed ID: 30122084
[TBL] [Abstract][Full Text] [Related]
4. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
5. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
Stein EM; Bonifacio G; Latrémouille-Viau D; Shi S; Guérin A; Wu EQ; Sadek I; Cao X
J Med Econ; 2021; 24(1):234-243. PubMed ID: 33472483
[TBL] [Abstract][Full Text] [Related]
6. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States.
Bell JA; Galaznik A; Farrelly E; Blazer M; Murty S; Ogbonnaya A; Eaddy M; Fram RJ; Faller DV; Kota V
Leuk Res; 2018 Aug; 71():27-33. PubMed ID: 29944984
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations.
Stein EM; Bonifacio G; Latremouille-Viau D; Guerin A; Shi S; Gagnon-Sanschagrin P; Briggs O; Joseph GJ
J Med Econ; 2018 Jun; 21(6):556-563. PubMed ID: 29304724
[TBL] [Abstract][Full Text] [Related]
8. Reduced mortality, complications, and economic burden among medicare beneficiaries receiving influenza antivirals.
Best JH; Reddy SR; Chang E; Bognar K; Tarbox MH; Cagas SE; Seetasith A
J Med Econ; 2024; 27(1):240-252. PubMed ID: 38294309
[TBL] [Abstract][Full Text] [Related]
9. Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson S; Horvath Walsh LE; Wade RL
Adv Ther; 2019 Aug; 36(8):1922-1935. PubMed ID: 31222713
[TBL] [Abstract][Full Text] [Related]
10. Elderly patients with acute myeloid leukemia who only receive supportive care in the Surveillance, Epidemiology and End Results-Medicare database: demographics, treatment patterns and outcomes.
Dharmani C; Wang E; Tu N; Fofah O; Cueto J; Salas M; Kamel YM
Future Oncol; 2023 Aug; 19(24):1677-1693. PubMed ID: 37345543
[TBL] [Abstract][Full Text] [Related]
11. Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation.
Preussler JM; Meyer CL; Mau LW; Majhail NS; Denzen EM; Edsall KC; Farnia SH; Saber W; Burns LJ; Vanness DJ
Biol Blood Marrow Transplant; 2017 Jun; 23(6):1021-1028. PubMed ID: 28263920
[TBL] [Abstract][Full Text] [Related]
12. Economic Burden of Veno-occlusive Disease in Patients With B-cell Acute Lymphoblastic Leukemia in the United States.
Zhang X; Song X; Lopez-Gonzalez L; Jariwala-Parikh K; Romanov V; Cong Z
Clin Ther; 2018 Oct; 40(10):1711-1719.e1. PubMed ID: 30196935
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.
Jabbour EJ; Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
J Med Econ; 2017 Sep; 20(9):1007-1012. PubMed ID: 28681664
[TBL] [Abstract][Full Text] [Related]
14. Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis.
Yang J; Boytsov N; Carlson JJ; Barthold D
J Manag Care Spec Pharm; 2023 Aug; 29(8):917-926. PubMed ID: 37523320
[No Abstract] [Full Text] [Related]
15. Incidence, economic burden, and treatment of acute respiratory tract infection in hematopoietic stem cell transplantation recipients using real world data in Japan: a retrospective claims data analysis.
Wattanakamolkul K; Nakayama Y
J Med Econ; 2022; 25(1):870-879. PubMed ID: 35703058
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015-2020.
Huntington SF; Ingham MP; Okonkwo L; Singh A; Wang R; Ammann EM
Leuk Lymphoma; 2022 May; 63(5):1180-1190. PubMed ID: 34913805
[TBL] [Abstract][Full Text] [Related]
17. Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis.
Bonafede M; Anaissie E; Evans K; Itzler R
BMC Health Serv Res; 2021 Oct; 21(1):1125. PubMed ID: 34666775
[TBL] [Abstract][Full Text] [Related]
18. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and outcomes of elderly patients with acute myeloid leukemia who receive no treatment in the Surveillance, Epidemiology and End Results-Medicare database.
Dharmani C; Wang E; Tu N; Salas M; Kamel YM
Future Oncol; 2023 Jan; 19(2):159-171. PubMed ID: 36912693
[TBL] [Abstract][Full Text] [Related]
20. Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States.
Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Lefebvre P; Pilon D; George D
J Med Econ; 2024; 27(1):381-391. PubMed ID: 38420699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
